Series of hepatitis B treatments enter Seoul National University Hospital, warning fierce competition
As Ildong Pharmaceutical’s ‘Besivo’ entered Seoul National University Hospital January after Gilead Sciences’ ‘Vemlidy’ last December, it has notified even fiercer competition in the chronic type B hepatitis market. The two products were also landed together on Severance Hospital last November....
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.